



Codes ATC: A03BB01

Indication	Palliative care
Type de médicament	Chemical agent
Type de liste	Liste de base
Formulations	Parenteral > General injections > unspecified: 20 mg per mL injection
Historique des statuts LME	Ajouté pour la première fois en 2013 (TRS 985)
Sexe	Tous
Âge	Adolescents et adultes
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets</a> .
Wikipédia	<a href="#">Hyoscine butylbromide</a>
DrugBank	<a href="#">Hyoscine butylbromide (Scopolamine butylbromide)</a>

## Résumé des preuves et recommandation du comité d'experts

Following a review of medicines for palliative care by the Expert Committee in 2013, hyoscine butylbromide was added to the core list of the EML for management of respiratory secretions in patients receiving palliative care. Although the evidence for the benefit to the patient of the use of antimuscarinic agents in prevention of accumulation of respiratory tract secretions during the dying phase was acknowledged as weak by the Expert Committee, the inclusion of hyoscine butylbromide (which, in contrast to the hydrobromide included for children, does not cross the blood-brain barrier) was supported.

